Innovative Drug May Revolutionize the Treatment of Early-Stage Breast Cancer

Researchers from a large-scale international study are now investigating whether standard endocrine therapy can be improved by the additional of palbociclib, a kinase inhibitor.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.